Audion touts Ph1 results for hearing loss drug

This article was originally published here

Audion Therapeutics logoAudion Therapeutics touted positive results yesterday from a Phase I trial of the company’s hearing loss drug.

In 15 people with mild to moderate sensorineural hearing loss, Audion tested the safety and tolerability of its LY3056480 mediated Notch inhibitor. The drug is designed to regenerate the inner ear sensory hair cells that are lost over time.

Get the full story at our sister site, Drug Delivery Business News.

The post Audion touts Ph1 results for hearing loss drug appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply